Parvovirus B 19 IgG ELISA kit (DEIA10283)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Intended Use
The Parvovirus B19 IgG (Recombinant) Enzyme Immunoassay Kit measures IgG-class antibodies to Parvovirus B19 in serum.
Contents of Kit
1. Microtiterwells: 12 x 8 (break apart) strips, 96 wells
2. Sample Diluent: 1 x 100 mL, ready to use
3. High Control: 1 x 1.0 mL, red cap
4. Low Control: 1 x 2.0 mL, yellow cap
5. Calibrator: 1 x 2.0 mL, black cap
6. Enzyme Conjugate: 1 x 20 mL
7. Substrate Solution, 1 vial, 14 mL
8. Stop Solution: 1 x 14 mL
9. Wash Solution: 1 x 30 mL (20x concentrated for 600 mL)


Have you cited DEIA10283 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Long-term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan


Authors: Onodera, Hiroyuki; Nakagawa, Risa; Nakagawa, Hitoshi; Urayama, Takeru; Haino, Katsuyuki; Yunoki, Mikihiro

BACKGROUND STUDY DESIGN AND METHODS Intravenous immunoglobulin (IVIG) contains immunoglobulin G against various viruses, except those that have been screened, such as human immunodeficiency and hepatitis C viruses. Antivirus titers reflect the serostatus of the blood donor population in the collection region and are of clinical interest. During the past 10 years, measles, mumps, rubella, varicella-zoster, hepatitis A and B, Epstein-Barr, and human respiratory syncytial viruses; human parainfluenza viruses 1, 2, and 3; human herpes simplex viruses 1 and 2; human herpesvirus 6; cytomegalovirus (CMV); human adenoviruses (HAdVs) 1, 2, 3, 7, and 11; human parvovirus B19; and human echovirus 9 and 11 titers in IVIG lots have been measured by a commercial testing facility. A viral neutralizing assay for CMV has been used at our facility. Herein, we summarize the measurements and results of a regression analysis of the trends in virus antibody titers. RESULTS CONCLUSION IVIG lots contained significant titers against all of the above viruses, except for HAdV 7. Three patterns-stable, increasing, and decreasing-were observed, without any drastic changes. Although these trends reflect the seroprevalence in Japan, the titers were not obviously affected by the cycle of epidemics. On the other hand, the prevalence data suggest that titers against hepatitis A virus and other viruses will decrease in the near future, although they are currently stable. Monitoring the titer of IVIG lots and seroprevalence of donor populations is important for anticipating future changes in virus antibody titers of IVIG lots and can provide useful information of clinical interest.

Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis


Authors: England, Bryant R.; Mikuls, Ted R.; Xie, Fenglong; Yang, Shuo; Chen, Lang; Curtis, Jeffrey R.

Objective. Histopathologic studies have Implicated herpes zoster (HZ) as a causative organism of giant cell arteritis (GCA). The purpose of this study was to assess the epidemiologic association of HZ events with incident GCA. Methods. We performed a retrospective cohort study in 2 large independent US administrative data sets: Medicare 5% and Truven Health Analytics MarketScan. Eligible subjects had 12 months of continuous coverage, were >50 years old, and had no history of GCA or polymyalgia rheumatica. HZ events (complicated and uncomplicated) and GCA were identified by the presence of International Classification of Diseases, Ninth Revision, Clinical Modification codes from physician visit or hospital discharge records. Antiviral therapies and vaccinations were identified from prescription claims and drug codes. Risk of incident GCA was calculated using multivariable Cox proportional hazards regression. Results. Among 16,686,345 subjects, a total of 5,942 GCA cases occurred, with 3.1% (MarketScan) and 6.0% (Medicare) having preceding HZ events. Unadjusted GCA incidence rates were highest in the groups with complicated and uncomplicated HZ. After multivariable adjustment, complicated HZ was associated with an increased risk of GCA (hazard ratio [HR] 1.99 [95% confidence interval (95% CI) 132-3.02] In the Medicare cohort and 2.16 [95% CI 1.46-3.18] in the MarketScan cohort), as was uncomplicated HZ (HR 1.42 [95% CI 1.02-1.99] and HR 1.45 [95% CI 1.05-2.01] in the respective cohorts). Vaccination and antiviral treatment were not consistently associated with GCA risk, although antiviral treatment was marginally associated with a decreased risk of GCA In the Medicare cohort (HR 0.67 [95% CI 0.46-41.99]). Conclusion. HZ is associated with an increased risk of GCA. The infrequency of HZ in GCA patients suggests that it is only one potential trigger for GCA. Antivirals and vaccination did not consistently mitigate this risk.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket